I chose to summarize an article about a new antifungal called eberconazole. Twenty to twenty-five percent of the world’s population is affected by a dermatophytic infection. This is a parasitic skin infection caused by a fungus. The most common species of fungi to cause dermatophytosis are Trichophyton, Epidermophyton, and Microsporum. It is caused by parasitic organisms attaching to the keratin on the skin. They feed on the keratin and form colonies. These infections are only limited to the superficial layers of the skin so topical antifungal agents are a great treatment. Although oral and topical antifungals can be used, topical treatments are the first line drugs of choice for localized dermatophytosis due to a decrease in the amount of adverse reactions, increased efficacy and aim in treatment, shorter treatment period needed, ease of use and application, decrease in treatment time, and increased compliance. There are a lot of antifungals on the market and choosing the best drug for treatment is made harder due to problems with diagnosing the infection, signs and symptoms that are not the norm for clinical presentation, the prevalence of drug resistant strains, the increasing population of immunocompromised people, and poor adherence to treatment. Eberconazole is an imidazole derivative that was originally launched on the market in Spain in 2005 by Laboratories Salvat and is now on the market in many countries. This article reviews the pharmacology of this drug and its clinical use and efficacy.
The molecular structure of eberconazole is C18H14Cl2N2. It is a broad spectrum antifungal that has be proven to be successful in fighting dermatophytosis, candidiasis, other yeast infections including Malassezzia furfur, and organisms that cause pityriasis versicolor when tested in vitro and in animals. It has also been proven effective against most triazole resistant yeasts, fluconazole resistant Candida albicans, and Gram-positive bacteria in vitro. It has anti-inflammatory abilities not seen in other imidazoles so it would be even effective in treating infections that cause inflammation. It is both fungicidal at higher concentrations and fungiostatic at lower concentrations. Eberconazole works by stopping the synthesis of ergosterol. It does this by inhibiting the enzyme responsible for forming the precursor to ergosterol which is essential to the cytoplasmic membrane. At low concentrations, eberconazole will inhibit sterol synthesis inside the cell by binding to the phospholipid layer of the cell. In higher concentrations it causes cell leakage of certain molecules which will eventually lead to cell death. Its anti-inflammatory property can be compared to those of aspirin and ketoprofen. This property is caused by restricting the activity of 5-lipooxygenase and decreasing the activity cyclooxygenase-2.
The activity of eberconazole was compared to clotrimazole, ketoconazole, and miconazole in one in vitro study against 200...